These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 37150034)

  • 21. Astragaloside IV ameliorates cisplatin-induced liver injury by modulating ferroptosis-dependent pathways.
    Guo J; Le Y; Yuan A; Liu J; Chen H; Qiu J; Wang C; Dou X; Yuan X; Lu D
    J Ethnopharmacol; 2024 Jun; 328():118080. PubMed ID: 38521426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Astragaloside IV protects against podocyte injury via SERCA2-dependent ER stress reduction and AMPKα-regulated autophagy induction in streptozotocin-induced diabetic nephropathy.
    Guo H; Wang Y; Zhang X; Zang Y; Zhang Y; Wang L; Wang H; Wang Y; Cao A; Peng W
    Sci Rep; 2017 Jul; 7(1):6852. PubMed ID: 28761152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chinese Herbal Medicine in Ameliorating Diabetic Kidney Disease via Activating Autophagy.
    Wang Y; Zhao H; Wang Q; Zhou X; Lu X; Liu T; Zhan Y; Li P
    J Diabetes Res; 2019; 2019():9030893. PubMed ID: 31828168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats.
    Chen J; Chen Y; Luo Y; Gui D; Huang J; He D
    Eur J Pharmacol; 2014 Aug; 736():86-94. PubMed ID: 24809932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Astragaloside IV from Astragalus membranaceus ameliorates renal interstitial fibrosis by inhibiting inflammation via TLR4/NF-кB in vivo and in vitro.
    Zhou X; Sun X; Gong X; Yang Y; Chen C; Shan G; Yao Q
    Int Immunopharmacol; 2017 Jan; 42():18-24. PubMed ID: 27855303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Research progress of astragaloside IV in treating acute kidney injury.
    Liu Y; Huang Y; Sun D; Ye N; Chen T; Yang M; Zhou L; Zou H
    Int Urol Nephrol; 2024 Aug; 56(8):2645-2650. PubMed ID: 38494585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects.
    Zhang J; Wu C; Gao L; Du G; Qin X
    Adv Pharmacol; 2020; 87():89-112. PubMed ID: 32089240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in Traditional Chinese Medicine research in diabetic kidney disease treatment.
    Shen S; Zhong H; Zhou X; Li G; Zhang C; Zhu Y; Yang Y
    Pharm Biol; 2024 Dec; 62(1):222-232. PubMed ID: 38357845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression.
    Gui D; Huang J; Guo Y; Chen J; Chen Y; Xiao W; Liu X; Wang N
    Cytokine; 2013 Mar; 61(3):970-7. PubMed ID: 23434274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Astragaloside IV: A promising natural neuroprotective agent for neurological disorders.
    Yao M; Zhang L; Wang L
    Biomed Pharmacother; 2023 Mar; 159():114229. PubMed ID: 36652731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An updated role of astragaloside IV in heart failure.
    Zang Y; Wan J; Zhang Z; Huang S; Liu X; Zhang W
    Biomed Pharmacother; 2020 Jun; 126():110012. PubMed ID: 32213428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Efficacy and Mechanism of Chinese Herbal Medicine on Diabetic Kidney Disease.
    Lu Z; Zhong Y; Liu W; Xiang L; Deng Y
    J Diabetes Res; 2019; 2019():2697672. PubMed ID: 31534972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Astragaloside IV protects against podocyte apoptosis by inhibiting oxidative stress via activating PPARγ-Klotho-FoxO1 axis in diabetic nephropathy.
    Xing L; Fang J; Zhu B; Wang L; Chen J; Wang Y; Huang J; Wang H; Yao X
    Life Sci; 2021 Mar; 269():119068. PubMed ID: 33476631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases.
    Tan YQ; Chen HW; Li J
    Drug Des Devel Ther; 2020; 14():3731-3746. PubMed ID: 32982178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AGE/RAGE in diabetic kidney disease and ageing kidney.
    Wu XQ; Zhang DD; Wang YN; Tan YQ; Yu XY; Zhao YY
    Free Radic Biol Med; 2021 Aug; 171():260-271. PubMed ID: 34019934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Astragaloside IV ameliorates high glucose‑induced renal tubular epithelial‑mesenchymal transition by blocking mTORC1/p70S6K signaling in HK‑2 cells.
    Chen X; Yang Y; Liu C; Chen Z; Wang D
    Int J Mol Med; 2019 Feb; 43(2):709-716. PubMed ID: 30483732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Astragaloside IV ameliorates motor deficits and dopaminergic neuron degeneration via inhibiting neuroinflammation and oxidative stress in a Parkinson's disease mouse model.
    Yang C; Mo Y; Xu E; Wen H; Wei R; Li S; Zheng J; Li W; Le B; Chen Y; Pan H; Huang S; Wang S; Wang Q
    Int Immunopharmacol; 2019 Oct; 75():105651. PubMed ID: 31401385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Untapping the Potential of Astragaloside IV in the Battle Against Respiratory Diseases.
    Tan J; Yi J; Cao X; Wang F; Xie S; Dai A
    Drug Des Devel Ther; 2023; 17():1963-1978. PubMed ID: 37426627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal protective effects of astragaloside IV, in diabetes mellitus kidney damage animal models: A systematic review, meta-analysis.
    Zhou XT; Zou JJ; Ao C; Gong DY; Chen X; Ma YR
    Pharmacol Res; 2020 Oct; 160():105192. PubMed ID: 32942018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Astragaloside IV protects against diabetic nephropathy via activating eNOS in streptozotocin diabetes-induced rats.
    Fan Y; Fan H; Zhu B; Zhou Y; Liu Q; Li P
    BMC Complement Altern Med; 2019 Dec; 19(1):355. PubMed ID: 31805910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.